Copy of News Paper publication for quarter ending 30, June, 2025 financial results .
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Limited has submitted to BSE (Scrip Code: 538965) a copy of the newspaper advertisement carrying its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025, published in 'Prajasakti' (Telugu) on 10 August 2025. The filing, dated 11 August 2025, is made to comply with Regulation 47 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, which mandates newspaper publication of quarterly results. The submission is signed by Managing Director Nagireddy Seelam. Specific financial numbers from the results are not visible in the extracted text as the Telugu clippings contain largely unrelated news content.
This is a routine regulatory compliance submission with no direct material impact on the stock price. It simply confirms that the company has met its SEBI-mandated disclosure requirement to publish its Q1 results in a newspaper. Investors should look for the actual Q1 financial numbers in the detailed results filing to assess business performance.